The American Society of Clinical Oncology’s CancerLinQ is partnering with Atropos Health in an effort to provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.
Palo Alto, Calif.-based Atropos Health and CancerLinQ will work together to provide a “digital consult” to pressing clinical questions that are important in tailoring treatment decisions. Participating clinicians on the CancerLinQ platform will be able to request an on-demand analysis of millions of aggregated de-identified records of similar patient cases and outcomes, which will be delivered within days in the form of a “Prognostogram” report, leveraging best-in-class, peer-reviewed observational research methodologies.
CancerLinQ is a real-world oncology data platform developed by ASCO that collects and aggregates longitudinal electronic health record data from oncology practices throughout the United States. CancerLinQ improves the quality of patient care and accelerates discovery by securely compiling, harmonizing, analyzing, and de-identifying vast amounts of information on patient characteristics (e.g., molecular profiles, comorbidities), treatments, and long-term side effects.
Atropos began as a research project at Stanford Medicine in 2011. The “Green Button” concept aimed to answer the question: What if pressing a virtual button could trigger a search of millions of similar, anonymized electronic records to instantly aggregate data to inform patient care?
The concept grew into a research project called the Clinical Informatics Consult service, with a proof of concept built at Stanford Health Care. Upon the successful completion of the pilot, Saurabh Gombar, Nigam Shah, and Brigham Hyde founded Atropos Health in late 2020 to democratize access to real-world evidence. It completed a seed funding round in the fall of 2020, by a group of institutional and individual investors including the Boston Millennia Founders Fund.
In 2021, Stanford Health Care partnered with Atropos to support clinical decision-making across its more than 2,000 affiliated physicians.
“At CancerLinQ, we are guided by our commitment to deliver solutions to oncologists that improve the quality of care for patients in concrete and measurable ways,” said Sean Khozin, M.D., M.P.H., chief executive officer of CancerLinQ, in a statement. “Our collaboration with Atropos Health will enable us to provide high-quality real-world evidence derived from diverse patient populations to help oncologist individualize treatment decisions at the point of care.”
“Atropos Health was founded to bring real-world evidence to providers, where care delivery can be impacted immediately with emerging data sets,” said Saurabh Gombar, M.D., chief medical officer and co-founder at Atropos Health, in a statement. “With CancerLinQ, we can bring insights directly to the clinic for vulnerable patients with cancer who need personalized, targeted care to maximize the chance of a positive outcome. Our goal is to ensure that this network of physicians has the tools and evidence to identify new treatments and deliver exceptional care to their patients.”
